Skip to main content
. 2016 Apr 7;11(4):e0153288. doi: 10.1371/journal.pone.0153288

Fig 5. ERK1/2, AKT and p38 in human DCs.

Fig 5

(A) ERK1/2 and p-ERK1/2 expressions: immature DCs were cultured in the absence or presence of DEX (2ng/ml), yohimbine (8ng/ml) and PD98059 (40μM). After 30 min, cells were harvested to test protein levels of ERK1/2 and p-ERK1/2; (B) AKT and p-AKT expressions: immature DCs were cultured in the absence or presence of DEX (2ng/ml), yohimbine (8ng/ml) and LY294002 (30μM). After 30 min, cells were harvested to test protein levels of AKT and p-AKT; (C) p38 and p-p38 expressions: immature DCs were cultured in the absence or presence of DEX (2ng/ml), yohimbine (8ng/ml) and SB203580 (30μM). After 30 min, cells were harvested to test protein levels of p38 and p-p38. (D) Immature DCs were cultured in the absence or presence of PD98059 (40Μ) for 30 min, followed by treatment with DEX (2ng/ml) for 30 min, then matured with TNF-α (100ng/ml). After 24hrs, cells were collected to test mRNA levels of IL-12 p35, IL-12 p40 and IL-23 p19; (E) Immature DCs were cultured in the absence or presence of LY294002 (30Μ) for 30 min, followed by treatment with DEX (2ng/ml) for 30 min, then matured with TNF-α (100ng/ml). After 24hrs, cells were collected to test mRNA levels of IL-12 p35, IL-12 p40 and IL-23 p19. The results are presented as mean±SD. *P<0.05.